Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Total Non-current Assets
All assets not expected to be converted to cash within one year.
Opus Genetics, Inc.NASDAQ: IRD
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 22.2% from a year ago
Total non-current assets stood at $186K at the end of Q1 FY2026, down 22.2% from a year earlier and down 6.5% from the prior quarter. Over 3 fiscal years it compounded at +221.3% a year.
Context
- Total non-current assets amounted to 0.3% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -22.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 199K USD
- Year-over-year change
- -21.0%
- 4-year CAGR
- +111.2%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 199K | -21.0% |
| FY2024 | 2024-12-31 | 252K | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 6K | -40.0% |
| FY2021 | 2021-12-31 | 10K | — |
Total Non-current Assets vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 total non-current assets of $186K is the lowest of the 10 companies compared; the peer median is $22.72M.
- Its year-over-year change of -22.2% is the 4th highest of 10, against a peer median of -33.3%.
- Total non-current assets amounts to 0.3% of total assets for IRD, versus a peer median of 20.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $91.17M | -48.5% | -22.5% | 48.9% | |
| Mar 2026 | $90.54M | -1.6% | +21.3% | 33.3% | |
| Mar 2026 | $85.78M | -12.6% | -16.8% | 72.9% | |
| Mar 2026 | $24.83M | -40.4% | -24.1% | 10.4% | |
| Mar 2026 | $22.72M | +7152.7% | +269.0% | 76.5% | |
| Mar 2026 | $12.13M | -33.3% | -61.5% | 6.1% | |
| Mar 2026 | $10.34M | -32.8% | -26.6% | 20.8% | |
| Mar 2026 | $535K | -98.9% | -67.1% | 0.4% | |
| Mar 2026 | $326K | -48.6% | -47.6% | 0.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | $186K | -22.2% | +221.3% | 0.3% |
| Peer median (excluding IRD) | $22.72M | -33.3% | -24.1% | 20.8% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.